Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price reached a new 52-week high during trading on Thursday . The stock traded as high as $117.88 and last traded at $113.70, with a volume of 793226 shares. The stock had previously closed at $115.54.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Wedbush boosted their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Stock Performance

The company has a market cap of $6.07 billion, a PE ratio of -26.77 and a beta of 1.22. The firm’s 50 day moving average is $100.75 and its 200-day moving average is $84.99.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. On average, analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Insider Buying and Selling

In other Dianthus Therapeutics news, Director Anne Mcgeorge sold 7,750 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the sale, the director directly owned 1,250 shares of the company’s stock, valued at $136,262.50. This trade represents a 86.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares of the company’s stock, valued at $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 287,084 shares of company stock worth $29,615,923 over the last quarter. Corporate insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Nykredit A S purchased a new position in Dianthus Therapeutics during the second quarter worth about $147,000. Alyeska Investment Group L.P. grew its stake in shares of Dianthus Therapeutics by 188.2% in the 2nd quarter. Alyeska Investment Group L.P. now owns 150,592 shares of the company’s stock valued at $14,680,000 after buying an additional 98,345 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Dianthus Therapeutics by 24.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 75,396 shares of the company’s stock valued at $7,350,000 after buying an additional 14,961 shares during the period. Wellington Management Group LLP increased its holdings in shares of Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after buying an additional 634,099 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $574,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.